Skip to main
ZBIO
ZBIO logo

ZBIO Stock Forecast & Price Target

ZBIO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zenas BioPharma Inc. has positioned itself to capture a significant share of the $3 billion market opportunity in IgG4-RD, thanks to its innovative I&I product candidate, obexelimab, which offers a unique mechanism of action by targeting both CD19 and FcγRIIb without depleting B cells. The company is well-capitalized with approximately $350 million on its balance sheet, allowing it to sustain operations and invest in upcoming clinical trials, with top-line results for systemic lupus erythematosus (SLE) expected in the first half of 2026. With multiple catalyst events anticipated over the next 18 months and a focus on demonstrating differentiated efficacy in conditions like relapsing multiple sclerosis, Zenas BioPharma is likely to draw increasing investor interest.

Bears say

Zenas BioPharma Inc reported a significant net loss of $52.6 million for the fourth quarter of 2024 and a total net loss of $157 million for the full year, reflecting ongoing operational challenges. The company's reliance on its developmental candidate obexelimab, amidst risks of potential Phase II/III study failures and the need for additional financing, further complicates its financial outlook. Additionally, with the stock currently trading below cash levels, the absence of a clear path to achieving peak commercial revenue and concerns over competition raise substantial doubts about the sustainability of the business model.

ZBIO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zenas Biopharma Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zenas Biopharma Inc (ZBIO) Forecast

Analysts have given ZBIO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ZBIO has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zenas Biopharma Inc (ZBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.